Immuno-Oncology Tops Embolization for Intermediate-Grade Liver Cancer

(MedPage Today) — SAN FRANCISCO — An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended treatment benefit versus transarterial chemoembolization (TACE), according to an interim analysis…